UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus

Journal of hepatology, 2017, Vol.66 (1), p.S255-S255

2017

Volltextzugriff (PDF)

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

Journal of hepatology, 2017, Vol.66 (1), p.S513-S514

2017

Volltextzugriff (PDF)

An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks

Journal of hepatology, 2017, Vol.66 (1), p.S732-S733

2017

Volltextzugriff (PDF)

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target

Journal of hepatology, 2015-04, Vol.62, p.S267-S267

2015

Volltextzugriff (PDF)

1196 CLINICAL STUDY: METABOLIC INHIBITION OF VLDL AND ASSOCIATED HCV PRODUCTION BY A SINGLE ORAL DOSE OF NARINGENIN NANOCOMPLEX

Journal of hepatology, 2012-04, Vol.56, p.S474-S474

2012

Volltextzugriff (PDF)

P1161 PERI-TRANSPLANT TREATMENT WITH ANTI-HCV E2 HUMAN MONOCLONAL ANTIBODY MBL-HCV1 IN COMBINATION WITH A PROTEASE INHIBITOR RESULTS IN UNDETECTABLE HCVRNA IN THE EARLY POST-TRANSPLANT PERIOD

Journal of hepatology, 2014-04, Vol.60 (1), p.S471-S471

2014

Volltextzugriff (PDF)

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

Journal of hepatology, 2016, Vol.64 (2), p.S139-S140

2016

Volltextzugriff (PDF)

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S46-S46

2014

Volltextzugriff (PDF)

763 NARINGENIN INHIBITS THE ASSEMBLY AND LONG-TERM PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS (HCV) PARTICLES THROUGH A PPAR-MEDIATED MECHANISM

Journal of hepatology, 2010, Vol.52, p.S297-S297

2010

Volltextzugriff (PDF)

Viral hepatocarcinogenesis

Oncogene, 2010-04, Vol.29 (16), p.2309-2324

2010

Volltextzugriff (PDF)

1336 IL28B GENETIC ATTRIBUTABLE RISK IN HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA AND DECOMPENSATED LIVER DISEASE

Journal of hepatology, 2011-03, Vol.54, p.S527-S528

2011

Volltextzugriff (PDF)

835 TIME TO HCVRNA UNDETECTABILITY SUPERSEDES BASELINE FACTORS IN PREDICTING SVR IN PATIENTS WITH HCV GENOTYPE 1

Journal of hepatology, 2008, Vol.48, p.S313-S313

2008

Volltextzugriff (PDF)

716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS

Journal of hepatology, 2012-04, Vol.56, p.S283-S283

2012

Volltextzugriff (PDF)

Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B

Obstetric anesthesia digest, 2018-09, Vol.38 (3), p.151-152

2018

Volltextzugriff (PDF)

253 ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2010, Vol.52, p.S106-S107

2010

Volltextzugriff (PDF)

303 SHIFTS IN CHILD–PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION

Journal of hepatology, 2010, Vol.52, p.S127-S127

2010

Volltextzugriff (PDF)

783 ASSOCIATION OF PRETREATMENT AND ON-TREATMENT FACTORS WITH NULL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN

Journal of hepatology, 2008, Vol.48, p.S292-S292

2008

Volltextzugriff (PDF)

Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience

The Journal of heart and lung transplantation, 2019-04, Vol.38 (4), p.S49-S50

2019

Volltextzugriff (PDF)

PL-07 HIV and TGF-β1 regulates HCV replication through multiple pathways

International journal of infectious diseases, 2008, Vol.12, p.S33-S33

2008

Volltextzugriff (PDF)

[92] VIRAL SEQUENCE EVOLUTION IN ACUTE HCV INFECTION

Journal of hepatology, 2007, Vol.46, p.S41-S42

2007

Volltextzugriff (PDF)

[463] DETECTION OF CD4+ T CELL RESPONSES IN PATIENTS WITH ACUTE HCV INFECTION IRRESPECTIVE OF CLINICAL OUTCOME

Journal of hepatology, 2007, Vol.46, p.S176-S176

2007

Volltextzugriff (PDF)

THU-150 - Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus

Journal of hepatology, 2017, Vol.66 (1), p.S255-S255

2017

Volltextzugriff (PDF)

Lamivudine Compared With Newer Antivirals for Prophylaxis of Hepatitis B Core Antibody Positive Livers: A Cost‐Effectiveness Analysis

American journal of transplantation, 2014-03, Vol.14 (3), p.629-634

2014

Volltextzugriff (PDF)

FRI-235 - SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

Journal of hepatology, 2017, Vol.66 (1), p.S513-S514

2017

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target

1196 CLINICAL STUDY: METABOLIC INHIBITION OF VLDL AND ASSOCIATED HCV PRODUCTION BY A SINGLE ORAL DOSE OF NARINGENIN NANOCOMPLEX

P1161 PERI-TRANSPLANT TREATMENT WITH ANTI-HCV E2 HUMAN MONOCLONAL ANTIBODY MBL-HCV1 IN COMBINATION WITH A PROTEASE INHIBITOR RESULTS IN UNDETECTABLE HCVRNA IN THE EARLY POST-TRANSPLANT PERIOD

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

763 NARINGENIN INHIBITS THE ASSEMBLY AND LONG-TERM PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS (HCV) PARTICLES THROUGH A PPAR-MEDIATED MECHANISM

Viral hepatocarcinogenesis

1336 IL28B GENETIC ATTRIBUTABLE RISK IN HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA AND DECOMPENSATED LIVER DISEASE

835 TIME TO HCVRNA UNDETECTABILITY SUPERSEDES BASELINE FACTORS IN PREDICTING SVR IN PATIENTS WITH HCV GENOTYPE 1

716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS

Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B

253 ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C

303 SHIFTS IN CHILD–PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION

783 ASSOCIATION OF PRETREATMENT AND ON-TREATMENT FACTORS WITH NULL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN

3 POPULATIONAL ANALYSIS REVEALS A LINK BETWEEN COMPLEX VIRAL ESCAPE FROM CD8+ T-CELL RESPONSES AND PROTECTION IN HCV INFECTION

Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience

PL-07 HIV and TGF-β1 regulates HCV replication through multiple pathways

[92] VIRAL SEQUENCE EVOLUTION IN ACUTE HCV INFECTION

[463] DETECTION OF CD4+ T CELL RESPONSES IN PATIENTS WITH ACUTE HCV INFECTION IRRESPECTIVE OF CLINICAL OUTCOME

THU-150 - Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus

Lamivudine Compared With Newer Antivirals for Prophylaxis of Hepatitis B Core Antibody Positive Livers: A Cost‐Effectiveness Analysis

FRI-235 - SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

Aktive Filter

Suchergebnisse filtern